[go: up one dir, main page]

AR082275A1 - Pirazolo[1,5-a]pirimidinas para tratamiento antiviral - Google Patents

Pirazolo[1,5-a]pirimidinas para tratamiento antiviral

Info

Publication number
AR082275A1
AR082275A1 ARP110102213A ARP110102213A AR082275A1 AR 082275 A1 AR082275 A1 AR 082275A1 AR P110102213 A ARP110102213 A AR P110102213A AR P110102213 A ARP110102213 A AR P110102213A AR 082275 A1 AR082275 A1 AR 082275A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
cycloalkyl
aryl
nr11c
Prior art date
Application number
ARP110102213A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR082275A1 publication Critical patent/AR082275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La solicitud proporciona compuestos de la fórmula (1) o la fórmula (2) o una de sus sales o ésteres farmacéuticamente aceptables, tal como se describe en la presente. Los compuestos y composiciones de ellos son de utilidad para tratar infecciones por virus Pneumovirinae. Los compuestos, composiciones y métodos provistos son particularmente útiles para el tratamiento de infecciones por el virus sincicial respiratorio humano.Reivindicación 1: Un compuesto de la fórmula (1) o fórmula (2) o una de sus sales o ésteres farmacéuticamente aceptables; en donde A es -(C(R4)2)n-, en donde cualquiera de C(R4)2 de dicho -(C(R4)2)n- puede estar opcionalmente reemplazado por -O-, -S-, -S(O)p-, NH o NRa; n es 3, 4, 5 ó 6; cada p es 1 ó 2; Ar es un grupo heterociclilo C2-20 o un grupo arilo C6-20, en donde el heterociclilo C2-20 o el grupo arilo C6-20 está opcionalmente sustituido con 1 a 5 R6; X es -C(R13)(R14)-, -N(CH2R14)- o X está ausente; Y es N o CR7; cada R1, R2, R3, R4, R5, R6, R7 o R8 es, de modo independiente, H, oxo, OR11, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, N3, CN, NO2, SR11, S(O)pRa, NR11S(O)pRa, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)p(OR11), -SO2NR11R12, -NR11S(O)p(OR11), -NR11S(O)pNR11R12, NR11C(=NR11)NR11R12, halógeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilalquilo C1-8, arilo C6-20, heterociclilo C2-20, cicloalquilo C3-7 o carbociclilalquilo C4-8; dos R4 en átomos de carbono adyacentes, cuando se toman juntos, pueden formar un enlace doble entre los dos carbonos a los que están unidos o pueden formar un anillo cicloalquilo C3-7, en donde un átomo de carbono de dicho anillo cicloalquilo C3-7 puede estar reemplazado opcionalmente por -O-, -S-, -S(O)p-, -NH- o -NRa-; cuatro R4 en átomos de carbono adyacentes, cuando se toman juntos, pueden formar un anillo arilo C6 opcionalmente sustituido; dos R4 en el mismo átomo de carbono, cuando se toman juntos, pueden formar un anillo cicloalquilo C3-7 en donde un átomo de carbono de dicho anillo cicloalquilo C3-7 puede estar reemplazado opcionalmente por -O-, -S-, -S(O)p-, -NH- o -NRa-; dos R6 en átomos de carbono adyacentes, cuando se toman juntos, pueden formar un anillo cicloalquilo C3-7 en donde un átomo de carbono de dicho anillo cicloalquilo C3-7 puede estar reemplazado opcionalmente por -O-, -S-, -S(O)p-, -NH- o -NRa-; cualquier R6 adyacente al grupo carbonilo obligado de dicho Ar, cuando se toma junto con R3, pueden formar un enlace o un grupo (C(R5)2)m, en donde m es 1 ó 2; cualquier R6 adyacente al grupo carbonilo obligado de dicho Ar, cuando se toma junto con R2, pueden formar un enlace; cada Ra es, de modo independiente, alquilo C1-8, haloalquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilalquilo C1-8, arilo C6-20, heterociclilo C2-20, cicloalquilo C3-7 o carbociclilalquilo C4-8, en donde cualquier alquilo C1-8, haloalquilo C1-8, alquenilo C2-8 o alquinilo C2-8 de Ra está opcionalmente sustituido con uno o varios OH, NH2, CO2H, heterociclilo C2-20 y en donde cualquier arilalquilo C1-8, arilo C6-20, heterociclilo C2-20, cicloalquilo C3-7 o carbociclilalquilo C4-8 de Ra está opcionalmente sustituido con uno o varios OH, NH2, CO2H, heterociclilo C2-20 o alquilo C1-8; cada R11 o R12 es, de modo independiente, H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilalquilo C1-8, arilo C6-20, heterociclilo C2-20, cicloalquilo C3-7, carbociclilalquilo C4-8, -C(=O)Ra, -S(O)pRa o arilalquilo C1-8; o R11 y R12 tomados junto con un nitrógeno al que ambos están unidos, forman un anillo heterocíclico de 3 a 7 miembros, en donde cualquier átomo de carbono de dicho anillo heterocíclico puede estar opcionalmente reemplazado por -O-, -S-, -S(O)p-, -NH-, -NRa- o -C(O)-; R13 es H o alquilo C1-8; R14 es H o alquilo C1-8, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, -NR11S(O)p(OR11) o NR11S(O)pNR11R12 y en donde cada alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilalquilo C1-8, arilo C6-20, heterociclilo C2-20, cicloalquilo C3-7 o carbociclilalquilo C4-8 de cada R1, R2, R3, R4, R5, R6, R7, R8, R11 o R12 está opcionalmente sustituido, de modo independiente, con uno o varios oxo, halógeno, hidroxi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, alquilo C1-8, haloalquilo C1-8, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2, -C(=O)NHRa, -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 o Ra.
ARP110102213A 2010-06-24 2011-06-24 Pirazolo[1,5-a]pirimidinas para tratamiento antiviral AR082275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35812210P 2010-06-24 2010-06-24

Publications (1)

Publication Number Publication Date
AR082275A1 true AR082275A1 (es) 2012-11-28

Family

ID=44509853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102213A AR082275A1 (es) 2010-06-24 2011-06-24 Pirazolo[1,5-a]pirimidinas para tratamiento antiviral

Country Status (39)

Country Link
US (7) US8486938B2 (es)
EP (2) EP2585467B1 (es)
JP (4) JP5878171B2 (es)
KR (1) KR101970837B1 (es)
CN (2) CN102958933B (es)
AP (1) AP3417A (es)
AR (1) AR082275A1 (es)
AU (1) AU2011270798B2 (es)
BR (1) BR112012033117A2 (es)
CA (1) CA2800834C (es)
CL (1) CL2012003632A1 (es)
CO (1) CO6640297A2 (es)
CR (1) CR20130023A (es)
CY (1) CY1118239T1 (es)
DK (1) DK2585467T3 (es)
EA (2) EA201591390A1 (es)
EC (2) ECSP13012400A (es)
ES (2) ES2700542T3 (es)
HK (2) HK1223934A1 (es)
HR (1) HRP20160431T1 (es)
HU (1) HUE029174T2 (es)
IL (2) IL223253B (es)
MA (1) MA34392B1 (es)
ME (1) ME02397B (es)
MX (1) MX2012015292A (es)
NZ (1) NZ604345A (es)
PE (1) PE20130395A1 (es)
PH (1) PH12012502528A1 (es)
PL (1) PL2585467T3 (es)
PT (1) PT3012258T (es)
RS (1) RS54761B1 (es)
SG (2) SG10201505022WA (es)
SI (1) SI2585467T1 (es)
SM (1) SMT201600155B (es)
TW (3) TWI537272B (es)
UA (1) UA112292C2 (es)
UY (1) UY33467A (es)
WO (1) WO2011163518A1 (es)
ZA (1) ZA201209549B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791166C (en) * 2010-02-26 2014-12-30 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as pde10 inhibitors
ES2700542T3 (es) 2010-06-24 2019-02-18 Gilead Sciences Inc Composición farmacéutica que comprende un derivado de pirazolo[1,5-A]pirimidina como un agente antiviral
NZ605889A (en) 2010-06-24 2014-10-31 Takeda Pharmaceutical Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
CN105360132A (zh) 2010-11-03 2016-03-02 陶氏益农公司 杀虫组合物和与其相关的方法
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
JP5531066B2 (ja) * 2011-08-24 2014-06-25 田辺三菱製薬株式会社 ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用
PH12014500930A1 (en) 2011-10-26 2014-06-09 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2794611B1 (en) * 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
CA2870024C (en) * 2012-04-17 2020-04-07 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US8901153B2 (en) 2012-04-27 2014-12-02 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
NZ707432A (en) 2012-11-16 2020-01-31 Univ Health Network Pyrazolopyrimidine compounds
HRP20180859T1 (hr) 2012-12-07 2018-07-13 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
CN110101699A (zh) 2013-03-15 2019-08-09 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
JP6485817B2 (ja) 2013-08-21 2019-03-20 ヤンセン バイオファーマ インク． 抗ウイルス化合物
EP3057426A4 (en) 2013-10-17 2017-03-29 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CA2925595A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
WO2015058021A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
MX2016005310A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
AU2014340412B2 (en) 2013-10-22 2017-04-20 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016535024A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
NZ720023A (en) 2013-10-22 2017-09-29 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
NZ719754A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
KR20160074640A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
KR20160074581A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
WO2015061163A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
TW201519786A (zh) 2013-10-22 2015-06-01 陶氏農業科學公司 殺蟲組成物及相關方法（一）
JP2016535025A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
JP2016534068A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
CA2926433A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
EP3062619B1 (en) 2013-10-22 2019-07-24 Dow AgroSciences LLC Pesticidal compositions and related methods
EP3060050A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
JP2016536307A (ja) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
JP2016538265A (ja) 2013-10-22 2016-12-08 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
NZ719541A (en) 2013-10-22 2017-11-24 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
HRP20192183T1 (hr) 2013-12-06 2020-02-21 Vertex Pharmaceuticals Inc. Spoj 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida koristan kao inhibitor atr kinase, njegova priprava, različiti kruti oblici te njegovi radioaktivno označeni derivati
EP3152212B9 (en) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
EP3157566B1 (en) 2014-06-17 2019-05-01 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016014398A1 (en) * 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
KR20170039121A (ko) 2014-07-31 2017-04-10 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
CN106488909A (zh) 2014-07-31 2017-03-08 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
RU2017106742A (ru) * 2014-08-05 2018-09-06 Элиос Биофарма, Инк. Комбинированная терапия для лечения парамиксовируса
KR20170042714A (ko) 2014-08-19 2017-04-19 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
JP2017528469A (ja) 2014-09-12 2017-09-28 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
KR102486023B1 (ko) 2014-12-08 2023-01-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 삼환식 피라졸로［１，５―ａ］피리미딘 유도체
MX368162B (es) * 2014-12-08 2019-09-20 Janssen Sciences Ireland Uc Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
PL3261639T3 (pl) * 2015-02-27 2022-12-19 Verseon International Corporation Podstawione związki pirazolowe jako inhibitory proteazy serynowej
JP2018076234A (ja) * 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
KR102411150B1 (ko) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. 세포 대사 과정의 억제제
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
BR112019008372B1 (pt) 2016-12-29 2021-11-09 Dow Agrosciences Llc Processo para preparação de compostos pesticidas
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3687543B1 (en) 2017-09-29 2024-03-20 Enanta Pharmaceuticals, Inc. Combinations of pharmaceutical agents as rsv inhibitors
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
EP3746444B1 (en) 2018-01-31 2023-09-27 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
CA3095277A1 (en) * 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against rsv
CN113194983B (zh) 2018-09-06 2025-11-18 奇达拉治疗公司 用于治疗病毒感染的组合物及方法
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
EP3903788A4 (en) * 2018-12-27 2022-09-07 Taisho Pharmaceutical Co., Ltd. PYRAZOLO[1,5-A] PYRIMIDINE MACROCYCLIC COMPOUND
WO2020135771A1 (zh) 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
WO2021050612A1 (en) * 2019-09-09 2021-03-18 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
PH12022551623A1 (en) 2020-01-13 2023-11-29 Verge Analytics Inc Substituted pyrazolo-pyrimidines and uses thereof
WO2022086993A1 (en) * 2020-10-19 2022-04-28 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
CN119546590A (zh) 2022-05-13 2025-02-28 默沙东有限责任公司 人呼吸道合胞病毒和偏肺病毒的抑制剂
NL2035306B1 (en) * 2023-07-07 2025-01-14 Academisch Ziekenhuis Leiden 1,3-isoindolinedione derivatives and heteroaromatic analogues for stimulating endothelial cell-pericyte interaction

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6342501B1 (en) * 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
US5543413A (en) * 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
IL137922A0 (en) 1998-02-17 2001-10-31 Tularik Inc Anti-viral pyrimidine derivatives
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
TWI225488B (en) 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
EP1485384A1 (en) 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
AU2003228770A1 (en) * 2002-05-10 2003-11-11 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
DE10247271A1 (de) 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
EP2287167A1 (en) * 2003-12-24 2011-02-23 Biota Scientific Management Pty. Ltd. Polycyclic agents for the treatment of respiratory syncytial virus infections
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
EP2229459B1 (en) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
BRPI0908529A2 (pt) 2008-02-26 2015-09-29 Novartis Ag composto orgânicos
WO2009126691A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US20110275673A1 (en) 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
EP2182081B1 (de) 2008-10-29 2014-01-22 Neue Materialien Bayreuth GmbH Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers
EP2682393A1 (en) 2008-12-03 2014-01-08 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A comprising a bicyclic core.
WO2010080357A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
JP5642661B2 (ja) 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
ES2700542T3 (es) 2010-06-24 2019-02-18 Gilead Sciences Inc Composición farmacéutica que comprende un derivado de pirazolo[1,5-A]pirimidina como un agente antiviral
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
CA2870024C (en) 2012-04-17 2020-04-07 Gilead Sciences, Inc. Compounds and methods for antiviral treatment

Also Published As

Publication number Publication date
CA2800834A1 (en) 2011-12-29
PH12012502528A1 (en) 2022-03-21
AP3417A (en) 2015-09-30
KR101970837B1 (ko) 2019-04-19
RS54761B1 (sr) 2016-10-31
CN102958933A (zh) 2013-03-06
CR20130023A (es) 2013-03-25
MA34392B1 (fr) 2013-07-03
US20170362244A1 (en) 2017-12-21
EP3012258A1 (en) 2016-04-27
MX2012015292A (es) 2013-05-30
AP2013006686A0 (en) 2013-01-31
US20120003215A1 (en) 2012-01-05
PE20130395A1 (es) 2013-04-10
ECSP17084267A (es) 2018-01-31
TW201639576A (zh) 2016-11-16
EP3012258B1 (en) 2018-09-19
SG186291A1 (en) 2013-02-28
CL2012003632A1 (es) 2013-11-04
IL257410A (en) 2018-04-30
TWI537272B (zh) 2016-06-11
CY1118239T1 (el) 2017-06-28
TW201213332A (en) 2012-04-01
US20160130275A1 (en) 2016-05-12
IL223253B (en) 2018-02-28
ME02397B (me) 2016-09-20
JP2015218176A (ja) 2015-12-07
EA023223B1 (ru) 2016-05-31
ES2700542T3 (es) 2019-02-18
UA112292C2 (uk) 2016-08-25
PL2585467T3 (pl) 2016-09-30
EA201591390A1 (ru) 2016-06-30
HK1221715A1 (zh) 2017-06-09
CN105481866A (zh) 2016-04-13
WO2011163518A1 (en) 2011-12-29
US20140154240A1 (en) 2014-06-05
EP2585467B1 (en) 2016-03-02
SG10201505022WA (en) 2015-07-30
BR112012033117A2 (pt) 2016-11-22
CA2800834C (en) 2018-10-23
IL223253A0 (en) 2013-02-03
NZ604345A (en) 2015-02-27
ZA201209549B (en) 2015-07-29
TW201529578A (zh) 2015-08-01
JP2020059750A (ja) 2020-04-16
KR20140032333A (ko) 2014-03-14
PT3012258T (pt) 2018-12-14
US20170190708A1 (en) 2017-07-06
US9238039B2 (en) 2016-01-19
JP6684552B2 (ja) 2020-04-22
JP2013534524A (ja) 2013-09-05
JP5878171B2 (ja) 2016-03-08
US9957275B2 (en) 2018-05-01
UY33467A (es) 2012-01-31
TWI476201B (zh) 2015-03-11
AU2011270798B2 (en) 2015-03-19
ES2571334T3 (es) 2016-05-24
TWI626050B (zh) 2018-06-11
DK2585467T3 (en) 2016-06-13
SI2585467T1 (sl) 2016-04-29
JP2017019850A (ja) 2017-01-26
US8486938B2 (en) 2013-07-16
ECSP13012400A (es) 2013-03-28
EP2585467A1 (en) 2013-05-01
HRP20160431T1 (hr) 2016-05-20
SMT201600155B (it) 2016-07-01
HUE029174T2 (hu) 2017-02-28
US20140072554A1 (en) 2014-03-13
CN102958933B (zh) 2016-02-03
CO6640297A2 (es) 2013-03-22
EA201291172A1 (ru) 2013-05-30
US8809330B2 (en) 2014-08-19
HK1223934A1 (en) 2017-08-11
AU2011270798A1 (en) 2013-01-24
US20180298011A1 (en) 2018-10-18
HK1184157A1 (zh) 2014-01-17

Similar Documents

Publication Publication Date Title
AR082275A1 (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
AR084389A1 (es) Compuestos de nucleosidos 1’-carba sustituidos para tratamiento antiviral
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
HRP20191754T1 (hr) Spojevi i postupci za antivirusno liječenje
ES2524398T3 (es) Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
AR078012A1 (es) Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
MX375432B (es) Inhibidores de la replicacion de los virus de la gripe.
ECSP13012418A (es) Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih
BR112013017316A2 (pt) compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
EA201590020A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
PH12015502429A1 (en) Dicarboxylic acid compound
BR112015028760A2 (pt) compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas
MX2014002949A (es) Compuesto de imidazopiridina, composiciones y metodos de uso.
MX2019012759A (es) Derivados de pirrolopirimidina utiles como inhibidores de la replicacion de los virus de la gripe.
AR080146A1 (es) Compuestos para tratar infecciones del virus sincicial respiratorio
EA201490573A1 (ru) Соединение бензотиазолона
RU2014123690A (ru) Терапевтическое средство при артрозе

Legal Events

Date Code Title Description
FB Suspension of granting procedure